GlassScriptPhysician profile
Steven Yablon
NPI 1699786251
$13,229.63
in general payments reported to CMS, 2019-2025
45 companies · $2,086 in 2025
The $2,086 reported for 2025 was more than what 90% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $927 · 2020: $1,009 · 2021: $1,618 · 2022: $2,463 · 2023: $2,800 · 2024: $2,328 · 2025: $2,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,044 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,044.10 |
| Education | $168.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,276.00 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $1,008.52 | 2019-2025 | Veltassa |
| Amgen INC. | $1,006.03 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Boehringer Ingelheim Pharmaceuticals, INC. | $783.98 | 2021-2025 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $585.08 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $549.78 | 2019-2025 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $502.71 | 2020-2025 | Acthar, Terlivaz |
| Aurinia Pharma U.S., INC. | $486.00 | 2021-2025 | Lupkynis |
| Fresenius USA Marketing, INC. | $454.86 | 2020-2025 | Velphoro, Velphoro, Korsuva |
| Novo Nordisk INC | $441.79 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $432.46 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $426.16 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $400.20 | 2019-2025 | |
| Glaxosmithkline, LLC. | $377.21 | 2020-2025 | Benlysta, Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $293.14 | 2019-2025 | Jynarque |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Yablon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.